Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been assigned a consensus recommendation of “Moderate Buy” from the eighteen ratings firms that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $54.94.

Several equities analysts have commented on NTLA shares. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th. Wedbush reissued a “neutral” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a research note on Monday, November 18th. William Blair restated a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a research note on Monday, November 18th. Canaccord Genuity Group reiterated a “buy” rating and issued a $90.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. Finally, Wells Fargo & Company dropped their price objective on Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating for the company in a research report on Monday, November 18th.

Insiders Place Their Bets

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the sale, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This represents a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. AdvisorNet Financial Inc boosted its holdings in shares of Intellia Therapeutics by 63.5% during the 2nd quarter. AdvisorNet Financial Inc now owns 5,100 shares of the company’s stock worth $114,000 after buying an additional 1,980 shares in the last quarter. Blue Trust Inc. boosted its stake in Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after acquiring an additional 1,398 shares in the last quarter. Intellectus Partners LLC boosted its stake in Intellia Therapeutics by 2.1% during the second quarter. Intellectus Partners LLC now owns 58,225 shares of the company’s stock worth $1,303,000 after acquiring an additional 1,225 shares in the last quarter. Raymond James & Associates grew its holdings in Intellia Therapeutics by 34.1% in the second quarter. Raymond James & Associates now owns 207,295 shares of the company’s stock worth $4,639,000 after purchasing an additional 52,671 shares during the period. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in Intellia Therapeutics in the second quarter valued at $893,000. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA opened at $12.90 on Wednesday. The business’s 50 day simple moving average is $16.13 and its 200 day simple moving average is $20.60. Intellia Therapeutics has a 1 year low of $12.47 and a 1 year high of $34.87. The company has a market capitalization of $1.31 billion, a P/E ratio of -2.37 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. During the same period last year, the company posted ($1.38) earnings per share. The business’s revenue for the quarter was down 24.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Intellia Therapeutics will post -5.12 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.